NANJING, China, Aug. 29, 2023 /PRNewswire/ — InxMed, a clinical-stage biotechnology company dedicates on developing innovative therapies targeting drug resistance for hard-to-treat solid tumors，announced today the first-in-class ADC OMTX705 has obtained the IND (Investigational New Drug)…